XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)
1 Months Ended 12 Months Ended
Jul. 15, 2021
$ / shares
shares
Sep. 15, 2021
$ / shares
shares
Dec. 30, 2020
USD ($)
$ / shares
shares
Jul. 02, 2020
Aug. 01, 2018
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Proceeds from reverse recapitalization (in Dollars) | $     $ 3,700,000        
Offering costs (in Dollars) | $             $ 2,300,000
Shares issued             2,407,500
Deferred underwriting fees (in Dollars) | $     2,100,000        
Underwriting fees (in Dollars) | $           $ 5,900,000  
Aggregate gross proceed warrants exercised (in Dollars per share) | $ / shares   $ 10,000          
Chardan unit purchase option 220,000            
Exercise price per share (in Dollars per share) | $ / shares $ 11.5            
Net issuance shares of common stock 54,083            
Warrants to purchase one-half of one share of common stock 49,166            
Clene nanomedicine contingent earnout milestone1 shares           3,333,333  
Clene nanomedicine contingent earnout milestone 1 price (in Dollars per share) | $ / shares           $ 15  
Clene nanomedicine contingent earnout milestone 2 shares           2,500,000  
Clene nanomedicine contingent earnout milestone 2 price (in Dollars per share) | $ / shares           $ 20  
Clene nanomedicine contingent earnout milestone 3 shares           2,500,000  
Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization           12,852  
Total clene nanomedicine contingent earnout shares           8,346,185  
Initial shareholders contingent earnout milestone1 shares           375,000  
Initial shareholders contingent earnout milestone 2 shares           375,000  
Reverse recapitalization [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Offering costs (in Dollars) | $     $ 5,900,000        
Clene Inc [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Common stock, par value (in Dollars per share) | $ / shares     $ 0.0001        
Shares cancelled upon reverse recapitalization     2,303,495        
Reverse recapitalization exchange ratio     0.1389        
Shares held in escrow, percentage     5.00%        
Shares held in escrow (in Shares)     2,716,958        
Common stock, share outstanding     59,526,171        
Clene Inc [Member] | Restricted Stock Units (RSUs) [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Shares issued     1,136,961        
Clene Nanomedicine [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Initial shareholders earn-out shares     750,000        
Common stock, share issued     54,339,012        
Shareholder ownership percentage     91.00%        
Chardan Capital Markets, LLC [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Sale of units, number of units issued         220,000    
Units issued, price per unit (in Dollars per share) | $ / shares         $ 11.5    
Exercise price (in Dollars per share) | $ / shares         $ 11.5    
LifeSci Capital LLC [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Services letter agreement, description       (i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents received by Clene Nanomedicine from the Tottenham’s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash, equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, 644,164 shares of Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18).      
Shares issued     644,164        
Tottenham [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Shareholder ownership percentage     4.00%        
PIPE [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Shareholder ownership percentage     4.00%        
Exchange Ratio [Member] | Clene Inc [Member] | Restricted Stock Units (RSUs) [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Shares held in escrow, percentage     5.00%        
Common Stock [Member] | Clene Inc [Member] | Restricted Stock Units (RSUs) [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Shares issued     370,101        
Common Stock [Member] | Clene Inc [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Reverse recapitalization exchange ratio     0.132        
Shares Issued, Value, Share-based Payment Arrangement, Forfeited (in Dollars) | $     $ 53,286,115        
Warrant outstanding     5,566,363        
Common Stock [Member] | PIPE [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Shares issued   1,002,250          
Warrant, Exercise Price, Increase (in Dollars per share) | $ / shares   $ 0.01          
Common Stock [Member] | Exchange Ratio [Member] | Clene Inc [Member]              
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]              
Shares issued     7,032,591        
Exchange ratio percentage     95.00%